This inventor holds 20 USPTO granted patents and 25 published patent applications, plus 1 CIPO patent, primarily in Nanoparticle Therapeutics. Top assignees: University of Central Florida Research Foundation Inc., Alnylam Pharmaceuticals, Inc., Memorial Sloan Kettering Cancer Center. Active years: 2014-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Orlando, FL (US) (2014 - 2015)
- New York, NY (US) (2015 - 2019)
- Oviedo, FL (US) (2014 - 2022)
- Cambridge, MA (US) (2021 - 2023)
Company Filing History:
11 out of 1,374 
9 out of 466 
2 out of 621 
Years Active: 2014-2026
Areas of Expertise:
Title: Charalambos Kaittanis: Innovator in RNAi Technology
Introduction
Charalambos Kaittanis is a prominent inventor based in Oviedo, Florida, known for his significant contributions to the field of RNA interference (RNAi) technology. With a total of 16 patents to his name, Kaittanis has made remarkable strides in developing innovative solutions for various medical conditions.
Latest Patents
One of his latest patents focuses on "Complement component C3 iRNA compositions and methods of use thereof." This invention relates to RNAi agents, specifically double-stranded RNA (dsRNA) agents, that target the complement component C3 gene (C3). The patent outlines methods for using these RNAi agents to inhibit the expression of the C3 gene, which can be crucial in preventing and treating C3-associated disorders. These disorders include cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria (PNH), lupus nephritis (LN), bullous pemphigoid, and various forms of pemphigus, such as Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), as well as C3 glomerulopathy.
Career Highlights
Throughout his career, Kaittanis has worked with notable organizations, including the University of Central Florida Research Foundation, Inc. and Alnylam Pharmaceuticals, Inc. His work has significantly impacted the development of RNAi therapies, showcasing his dedication to advancing medical science.
Collaborations
Kaittanis has collaborated with esteemed colleagues, including Santimukul Santra and Atul Asati, further enhancing the innovative research in his field.
Conclusion
Charalambos Kaittanis stands out as a leading inventor in RNAi technology, with a focus on addressing critical health issues through his innovative patents. His contributions continue to pave the way for advancements in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile